COVID-19 Patient Management at Home and Hospital Today, an Essential Conversation

The treatment and management of COVID-19 patients is evolving rapidly. There is a global effort to discover novel treatments and test existing therapies that are safe and effective.

To date, the FDA has only granted a few Emergency Use Authorizations (EUA) for COVID-19 related treatments including: Remdesivir from Gilead Sciences (NASDAQ – GILD), convalescent plasma and gammaCore SapphireTM CV from electroCore, Inc. (NASDAQ – ECOR). More innovation is needed faster.

David Shulkin, MD, 9th Secretary of Veterans Affairs, will moderate a 45 minute Essential Conversation on COVID-19 therapeutics and management of the virus with patients at home and in the hospital with medical leaders on the front line of the fight against COVID-19. Q&A with participants will follow.

We look forward to your participation and approaches to improving COVID19 patient care.   

Important Safety Information:

·           Headache: Instructions for Use and Important Safety Information

·           EAU: Instructions for Use and Important Safety Information

·          Additional EUA information: gammaCore Sapphire CV (nVNS) has received  Emergency Use Authorization to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma related dyspnea and reduced airflow.

·         Authorization Letter: https://www.fda.gov/media/139967/download

·         Fact Sheet forHCPs: https://www.fda.gov/media/139968/download

·         Fact Sheet for Patients: https://www.fda.gov/media/139969/download

·         Instructions for gammaCore Use: https://www.fda.gov/media/139969/download